View Regeneron Pharmaceuticals, Inc. (REGN) current and estimated P/E ratio data provided by Seeking Alpha.
Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.
Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...
To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...
Hosted on MSN20d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteersTruveta, a health data startup launched in 2020, announced the massive undertaking Jan. 13 along with biotech firm Illumina and the Regeneron Genetics Center, an arm of Fortune 500 company ...
DNA sequencing company Illumina and biotech Regeneron have invested in electronic health record data company Truveta to create the largest and most diverse database of genetic information in the ...
Regeneron collaborates with Truveta and leading American health systems to massively extend its DNA-linked healthcare database to further advance scientific innovation and healthcare delivery ...
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback